Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland

Blach Sarah\textsuperscript{a}, Schaetti Christian\textsuperscript{b}, Bruggmann Philip\textsuperscript{c}, Negro Francesco\textsuperscript{d}, Razavi Homie\textsuperscript{a}

\textsuperscript{a} Center for Disease Analysis Foundation (CDAF), Lafayette, Colorado, USA  
\textsuperscript{b} Federal Office of Public Health, Public Health Directorate, Berne, Switzerland  
\textsuperscript{c} Arud Centres for Addiction Medicine, Zurich, Switzerland  
\textsuperscript{d} Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, Genève, Switzerland

Summary

BACKGROUND AND AIMS: A previous analysis of hepatitis C virus (HCV)-related healthcare costs in Switzerland found that the annual healthcare costs of untreated HCV infection (excluding antiviral treatment) could increase by more than 25 million Swiss francs (CHF) between 2013 and 2030. Since that publication, highly efficacious direct-acting antiviral therapies (DAAs) have become available, making HCV elimination a possibility. This analysis quantifies the clinical and economic burden of HCV intervention strategies over the next 15 years.

METHODS: A model was developed to estimate the future clinical and economic burden of HCV infection if patients are diagnosed and treated according to a historical paradigm (historical base case), or at higher levels without treatment reimbursement restrictions (Scenario 1). The infected population was tracked by age- and sex-defined cohorts, and associated direct medical costs (healthcare, screening, diagnostics and treatment) and quality-adjusted life years (QALYs) were calculated. Direct cost savings and the incremental cost-effectiveness ratio (ICER) were calculated to assess the economic impact of each scenario. Additionally, we generated a net-zero cost scenario (Scenario 2), assuming the same treatment paradigm as Scenario 1 but at the treatment price that would break even by 2031.

RESULTS: In the historical base case, annual direct costs are projected to decrease from 150 million (95% UI: 132–170 million) CHF in 2016 to 90 million (95% UI: 65–111 million) CHF in 2031. Cumulative direct costs are projected to reach 1.7 billion (95% UI: 1.2–2.0 billion) CHF by 2031. In Scenario 1, annual direct costs first increased to 175 million CHF by 2018, before declining to 44 million CHF by 2031. Cumulative direct costs in this scenario are projected to reach 1.8 billion CHF by 2031. For Scenario 2, the treatment price needed to achieve break-even by 2031 considering only direct costs would be 27,900 CHF per patient. By 2031, Scenarios 1 and 2 would gain 58,300 QALYs. In both scenarios, the ICER drops below the cost-effectiveness threshold of 78,000 CHF in 2018. Over the 15-year span, the ICER was determined to be 2,200 CHF for Scenario 1.

CONCLUSIONS: Increasing the number of patients treated and treating all fibrosis stages is cost-effective compared to the historical base case and could achieve break-even by 2031 at a price of 27,900 CHF.

Key words: hepatitis C virus, liver cirrhosis, hepatocellular carcinoma, Switzerland, cost-effectiveness, quality-adjusted life years, direct-acting antivirals

Introduction

Although the exact prevalence of the hepatitis C virus (HCV) in Switzerland is unknown, recent efforts by the Federal Office of Public Health (FOPH) suggest that in 2016 there were an estimated 39,500 (36,000–43,000) chronic infections nationwide\textsuperscript{2}. Switzerland is a world leader in harm reduction efforts which minimize ongoing transmission among people who inject drugs\textsuperscript{2}. However, previous research showed that HCV-related morbidity and
mortality are projected to increase by 2030, even as vi-
haem prevalence continues to decline [3]. In the absence of other interventions, healthcare costs will increase as the infected population ages because late-stage liver disease often requires costly healthcare procedures such as liver transplantation [3]. An analysis of HCV-related healthcare costs in Switzerland found that the annual healthcare costs of untreated HCV (excluding antiviral treatment) could increase from 86 (42–182) million Swiss francs (CHF) in 2013 to 112 (42–267) million CHF by 2030 [3]. This could place further strain on the limited resources of the healthcare system, as the economic costs incurred increase as in-
fec tion progresses.

In 2014, experts from across the country collaborated to propose a hepatitis elimination strategy, with the aim of curtailing new infections and addressing the harmful and costly impact of HCV as the prevalent population ages [4]. In previous modelling work, multiple scenarios with changes to sustained virological response (SVR) rates, medical eligibility, treatment uptake, diagnosis rates and the number of patients treated were developed and com-
pared [3]. This analysis builds on those efforts by assessing the forecasted impact and direct costs of intervention strategies, i.e., screening, diagnostic, staging and treatment costs, over the next 15 years. In particular, this analysis seeks to evaluate the clinical impact and associated cost of expanding treatment to patients in all fibrosis stages (≥F0) compared with the status quo until October 2017 (treat-
ment of ≥F2 patients), and to calculate a treatment price that is cost-saving (and cost-effective) by 2031. This analysis was not undertaken to recommend any one therapy over another; rather, it was conducted to estimate the impact of growing access to direct-acting antivirals (DAAs) on the HCV disease burden and associated costs.

**Methodology**

**Overview of approach and model**

We developed a disease burden and economic impact mod-
el, considering a formal Swiss healthcare sector perspec-
tive, to evaluate direct costs, health effects measured in quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER). Two HCV treatment sce-
narios, an intervention and a comparator scenario, were de-
veloped, considering the entire HCV RNA-positive pop-
ulation in Switzerland, and the outcomes were measured over a 15-year time horizon from 2016 to 2031. Addition-
ally, a net-zero cost scenario was developed in which the treatment price associated with the intervention scenario was calculated to achieve break-even by 2031.

Future costs and health effects were discounted at an an-
nual rate of 3%. A scenario was considered cost-effective when the ICER (calculated as net cost per QALY gained) was lower than the 2015 Swiss gross domestic product (GDP) per capita (78,000 CHF) [5].

Under the comparator, the “historical” base case, all individ-
uals aged 15 years and older with F2 or greater fibrosis (on the METAVIR scale) were eligible for treatment starting in 2016 (table 1). Under this base case, 2,000 ≥F2 pa-
tients were treated in 2016 at a price of 51,400 CHF. A trend to reduce treatment numbers annually after 2016 was applied to achieve a 50% reduction in the number of pa-
tients treated by 2020. This was intended to model the ex-
pected depletion of the pool of diagnosed and cared for pa-
tients which has been seen in the first few years of DAA treatment across Western countries.

The intervention scenario, Scenario 1, followed the same course as the historical base case through 2016 (table 1). In October 2017, reimbursement restrictions for all DAAs were lifted in Switzerland and the total number of patients treated for the year increased to 3,000. Beginning in 2018, 4,250 ≥F0 patients were modelled as being treated annually, at a price of 31,000 CHF per patient [6]. Under this inter-
vervention scenario, no changes were made to the number of diagnosed patients. A net-zero cost scenario, Scenario 2, was developed using the treatment paradigm of Scenario 1 but at a treatment price that would achieve zero net cost by 2031.

**Model structure**

The HCV disease progression model used in this analysis has been described previously [7] and detailed model structures, including model validation, are included in Ap-
pendix Section 1. Briefly, Swiss population, mortality and HCV epidemiology data were used to populate and cali-
b rate a Markov model that quantified the current and future disease burden of HCV infection in Switzerland. The disease burden was measured through forecasted outcomes of prevalence, mortality, and end-stage outcomes (including hepatocellular carcinoma (HCC) and decompensated cir-
rhosis (DC)), considering the impact of current and future interventions.

---

**Table 1:** Comparator (historical base case) and intervention (scenarios 1 and 2) scenario input parameters.

| Historical base case | 2016 | 2017 | 2018 | 2019 | 2020–2030 |
|----------------------|------|------|------|------|-----------|
| Treated              | 2,000| 1,800| 1,600| 1,400| 1,200     |
| Newly diagnosed      | 1,100| 1,100| 1,100| 1,100| 1,100     |
| Treatment-eligible fibrosis stages | ≥ F2 | ≥ F2 | ≥ F2 | ≥ F2 | ≥ F2 |
| New infections       | 700  | 700  | 700  | 700  | 700       |
| Treatment-eligible ages | 15+ | 15+ | 15+ | 15+ | 15+         |
| SVR                  | 95%  | 95%  | 95%  | 95%  | 95%       |

| Scenarios 1 and 2    | 2016 | 2017 | 2018 | 2019 | 2020–2030 |
|----------------------|------|------|------|------|-----------|
| Treated              | 2,000| 3,000| 4,300| 4,300| 4,300     |
| Newly diagnosed      | 1,100| 1,100| 1,100| 1,100| 1,100     |
| Treatment-eligible fibrosis stages | ≥ F2 | ≥ F0 | ≥ F0 | ≥ F0 | ≥ F0 |
| New infections       | 700  | 700  | 700  | 700  | 700       |
| Treatment-eligible ages | 15+ | 15+ | 15+ | 15+ | 15+         |
| SVR                  | 95%  | 95%  | 95%  | 95%  | 95%       |
Calculations for the economic model are provided in Appendix Section 3 and briefly described here. To assess cost-effectiveness, QALYs were calculated. QALYs were based on time spent in various health states, using a health state utility value between 0 and 1 (8-12). The incremental cost-effectiveness ratio (ICER) was calculated as the net cost (the difference in direct costs between the scenario and the base case) divided by the net benefit (the difference in QALYs between the scenario and the base case). Achieving a net cost of zero was defined as the break-even point.

Disease burden outcomes were evaluated through to 2030, in line with the Global Health Sector Strategy targets for the elimination of HCV [8]. However, the economic impact was considered through to 2031 to ensure all costs associated with implementing the intervention scenario were fully realized. Medical costs were denominated in 2016 Swiss francs, using the exchange rate on December 31, 2016.

**Input parameters**

Input parameters were obtained from peer-reviewed literature or extracted from Swiss-specific sources. The HCV disease progression model inputs for Switzerland have been published previously [3]. In many instances, however, more recent data (number treated, number diagnosed, etc.) were available. All updated and novel parameters are described below and in table 2.

A full list of the input parameters required for the HCV disease progression model is provided in Appendix Section 1. In summary, there were approximately 39,500 chronic (HCV RNA-positive) cases in Switzerland in 2016 [1]. The percentage diagnosed in 2016 was estimated from Swiss FOPH notification data were considered as follows. In 2013, there were an estimated 30,200 diagnosed viraemic infections in Switzerland (after accounting for mortality) [17]. In 2013–2015, there was an average of 1,600 new HCV notifications to the Swiss FOPH [10]. Assuming a viraemic rate of 79.7% [9], this suggests an average of 1,300 new viraemic diagnoses annually. Removing cured HCV patients over the 2004–2015 period results in a range of 25,400–29,100 total diagnosed viraemic cases alive in 2015 (table 2). In 2016, there were an additional 1,400 newly notified cases, corresponding to approximately 1,116 newly diagnosed viraemic cases [10]. Thus, out of the estimated 39,500 persons living with HCV in 2016, about 67–77% had been diagnosed.

The number of patients treated annually was derived from pharmaceutical sales data, and reimbursement restrictions on the basis of fibrosis stage were confirmed through discussions with the FOPH and providers in Switzerland. In 2015, an estimated 2,300 (2,000–2,500) patients were treated in total. Approximately 1,280 of these were ≥F3 and the remainder were F2 [11]. In 2016, the number of treated patients dropped to 2,100 ≥F2 (table 2). As of Oc-

---

**Table 2: HCV disease burden and economic impact module parameters.**

| Category                              | Item                              | Source                      | Year | Base Case | Sensitivity (run only where ranges are present) |
|---------------------------------------|-----------------------------------|-----------------------------|------|-----------|-----------------------------------------------|
| Disease burden model parameters       | Anti-HCV prevalence               | [1]                         | 2016 | 0.7       | 0.3–1.6% Beta-PERT                              |
|                                       | Viraemic rate                     | [5]                         |      | 79.7%     | -                                              |
|                                       | Viraemic diagnosed                | Calculated using data from [10, 1] | 1988–2012 | 27,300 | 25,500–29,100 Beta-PERT                        |
|                                       |                                   |                             | 2013–2015 | Refer to original source for annual data       | -                                              |
|                                       |                                   |                             | 2016   | 1,116     | -                                              |
|                                       | Treated                           | IMS Health [11] Expert Input (Prof. Franco Negro) | 2004–2014 | 10,670 | -                                              |
|                                       |                                   |                             | 2015   | 1,280 ≥F3 | 2,500 ≥F2                                    |
|                                       |                                   |                             | 2016   | 2,100 ≥F2 | -                                              |
|                                       | Liver transplants                 | Swiss Transplant            | 2003–2016 | Refer to original source for annual data       | -                                              |
|                                       | Liver transplants due to HCV      | Personal communication      | 21.2% | 18.2–49.2% | Beta-PERT                                    |
| Disease burden model validation       | Incident liver cancer cases       | National Institute for Cancer Epidemiology and Registration | 1988–2012 | Refer to original source for annual data | - |
|                                       | HCC etiology                      | Geneva Tumour Registry      | 1990–2013 | Refer to original source for annual data       | 25–90% Beta-PERT                               |
|                                       | HCC due to HCV                    | [12]                        | 1998–2012 | 44.5%     | 43.3–53.3% Beta-PERT                           |
| Economic modelling parameters         | Multiplier for private costs      | 1.5                         |       | -         |                                               |
|                                       | QALY health state utilities       | [13]                        | See study | Beta-PERT                                      |
|                                       | GDP per capita                    | 2015                        | 78,000 | -         |                                               |
|                                       | Discounting                       | 3%                          | 0%, 3% | Binomial |
| Screening costs (CHF) (public)        | Anti-HCV                          | [14, 15]                    | 2016   | 25        | 21–29 Beta-PERT                               |
|                                       | DNA test / PCR                    | [14, 15]                    | 2016   | 180       | 153–207 Beta-PERT                             |
|                                       | Genotyping                        | [14, 15]                    | 2016   | 180       | 153–207 Beta-PERT                             |
|                                       | Staging / liver biopsy / fibroscan| [14, 16]                    | 2016   | 256       | 218–294 Beta-PERT                             |
| Health state costs (CHF) (public)     | Average total cost                | [8]                         | 2015   | 59,100    | 49,100–66,400 Beta-PERT                       |
|                                       |                                   |                             | 2016   | 51,400    | 42,700–61,300 Beta-PERT                       |
|                                       |                                   |                             | 2017   | 31,000    | 26,350–35,650 Beta-PERT                       |
tober 2017, fibrosis restrictions were lifted, making all pa-
tients, regardless of their fibrosis stage, eligible for treat-
ment. In 2017, it was estimated that 3,000 patients were 
treated (based on extrapolations of data provided by the 
Swiss Pharmacist Cooperative (OFAC), Swiss National 
Pharmacy Service (Mediservice) and IMS Health), an 
increase of 43% compared to 2016 as previously ineligible 
F0 and F1 patients received treatment. All input parameters for the economic modelling are listed in 
table 2. QALY utilities were obtained from a 2016 cost-
effectiveness model of US patients and were applied to this 
model by disease stage [13]. Data on the cost of health-
care for HCV patients by disease stage [3, 14] and diagno-
cost data, including all treatment-related tests such as 
polymerase chain reaction (PCR) testing, genotyping and 
fibrosis staging [15], were obtained from previous publi-
cations. As treatment regimens and outcomes improve, 
the number and types of treatment-related tests needed are ex-
pected to change. The timeline for these changes was di-
vided into three waves, present (prior to 2018), near future 
(2018–2021) and pan-genotypic (after 2021). The FOPH specialties list provided treatment costs by ther-
apy type in 2016, when treatment was limited to ≥F2 pa-
tients, while October 2017 updates to the specialties list 
corresponding to the change in reimbursement restric-
tions were used to inform treatment costs for scenarios where ≥F0 patients were treated [6]. Discussions with the 
FOPH suggest that treatment costs decreased by 15% when 
treatment was expanded to F2 patients, so the treatment 
price of 59,100 CHF in 2015 (when treatment was restrict-
ed to ≥F3 patients) was assumed to be 15% higher than the baseline price in 2016 (51,400 CHF).

Characterizing uncertainty
Sensitivity analyses were carried out using Crystal Ball, 
an Excel add-in by Oracle. Beta-PERT distributions were 
used to model uncertainty in all study parameters, unless 
noted otherwise in table 2. A one-way sensitivity analysis 
was conducted to identify the variables that most heavily 
influenced the ICER. Additionally, a Monte Carlo simul-
ation with 1,000 trials was used to determine the 95% un-
certainty intervals (UIs).

Results
Disease burden analysis
The historical base case, with approximately 39,500 cases 
in 2016 and no change to the 2016 treatment paradigm, 
shows a decrease in the economic and disease burdens of 
HCV by 2031. The number of infected individuals decreases by 35% while rates of DC, HCC and liver-related deaths (LRD) decrease 50–55% by 2031 (Appendix Section 2). In comparison, in the intervention scenario (Scenario 1), an 85% decline in the projected number of viraemic cases is expected between 2016 and 2031, with approximately 560, 710 and 1,000 incident cases of DC, HCC and LRD re-
spectively averted over this period (Appendix Section 2).

Cost analysis
Under the historical base case, annual direct costs are pro-
tected to decrease from 150 million (95% UI: 132–170 
Table 2
| Year   | Cost (CHF) |
|--------|------------|
| 2016   | 150        |
| 2017   | 132        |
| 2018   | 125        |
| 2019   | 120        |
| 2020   | 115        |
| 2021   | 110        |
| 2022   | 105        |
| 2023   | 100        |
| 2024   | 95         |
| 2025   | 90         |
| 2026   | 85         |
| 2027   | 80         |
| 2028   | 75         |
| 2029   | 70         |
| 2030   | 65         |
| 2031   | 60         |

figure 1a

Swiss Med Wkly. 2019;149:w20026
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”. 
No commercial reuse without permission. See http://enm.ch/en/services/permissions.html.
standardized mortality ratio (SMR) for blood transfusion recipients accounted for more than 90% of the uncertainty. All the variables considered in the analysis are listed in table 2, and the impact on the 15-year ICER is presented in figure 2.

**Discussion**

The complex and costly-to-manage end-stage outcomes of chronic HCV infection, combined with high DAA costs, have previously led some health systems to require evi—

**Table 3**: Economic model outcomes for quality adjusted life-years gained, cumulative direct costs and ICER, by scenario, 2016–2031

| Outcomes for the 2016–2031 period | QALY's gained | Cumulative direct costs (CHF Millions) | ICER (CHF/QALY) |
|-----------------------------------|--------------|---------------------------------------|-----------------|
| Historical base case              | -            | 1,654                                 | -               |
| Scenario 1                        | 58,327       | 1,783                                 | 2,210           |
| Scenario 2                        | 58,327       | 1,654                                 | 0               |

QALY, quality-adjusted life year; CHF, Swiss franc; ICER, incremental cost-effectiveness ratio
dence of advanced liver fibrosis before authorizing new therapies [18–21]. This analysis sought to compare the impact of an intervention strategy of treating more patients in earlier fibrosis stages to the more restrictive base case. This was done by assessing the disease burden impact of this strategy, as well as the impact on direct costs and health effects (i.e. costs of reduced quality of life) over the next 15 years. Furthermore, the analysis sought to determine a drug price necessary for break-even by 2031.

Significant decreases in disease burden are estimated by 2031 for both the base case and the intervention scenario, with the intervention scenario seeing a larger impact, as expected. The decrease in late-stage liver disease in the base case scenario, however, is in contrast to previous analyses which reported a reduction in viraemic cases, but 50–85% increases in cases of DC, HCC and LRD by 2030 [3]. The current decrease in disease burden is likely due to increasing efforts in Switzerland to expand access to HCV diagnosis and treatment. Estimates from the FOPH suggest that 1,300 new viraemic cases were diagnosed annually between 2012 and 2015, and up to 2,000 ≥F2 patients were treated with DAAs in 2016, compared to 1,050 newly diagnosed and 1,100 treated patients, projected for the same years from prior studies [3, 10, 11, 17].

Direct costs were largely driven by treatment expansion. In the base case, annual direct costs decline over the 2017–2020 period due to the decreasing number of individuals already diagnosed and available to be treated. After 2020, the base case assumes no expansion of screening or diagnostic efforts and no increase to the number of patients treated, resulting in an equilibrium of direct costs (figure 1). By comparison, treatment and laboratory staging costs in the intervention scenarios remain greater than 130 million CHF annually until 2025, at which point they drop drastically as the limits of diagnosis and treatment are reached in Switzerland. The impact of the expanded access to treatment and cure in the intervention scenarios is also seen in the steady decline in healthcare costs, as cases of DC and HCC, as well as of liver transplantations, are prevented. By 2031, healthcare costs in the base case are four times greater than in the intervention scenarios.

![Figure 2: Sensitivity analysis around the average cost per QALY gained and explained variation by input variable, 2017–2031.](Image)

| Input Variable                              | Base   | Low     | High    | Explained Variation |
|---------------------------------------------|--------|---------|---------|---------------------|
| Progression (acute to spontaneous clearance)| 18.0%  | 15.9%   | 31.3%   | 33.62%              |
| Treatment price (2017)                      | 31,000 CHF | 28,110 CHF | 33,890 CHF | 61.22%              |
| anti-HCV prevalence (2016)                  | 0.7%   | 0.3%    | 1.6%    | 74.50%              |
| Progression (mild-to-moderate fibrosis)     | 4.5%   | 2.6%    | 6.9%    | 84.04%              |
| Standardized mortality ratio (transfusion)  | 2.1    | 1.3     | 17.6    | 88.10%              |
| Healthcare cost (compensated cirrhosis)     | 2,715 CHF | 1,841 CHF | 3,806 CHF | 91.98%              |
| Healthcare cost (F0-F3)                     | 479 CHF | 201 CHF | 948 CHF | 94.32%              |
| Progression (moderate fibrosis to cirrhosis)| 4.5%   | 2.6%    | 8.6%    | 96.24%              |
| Discount rate                               | 3%     | 0%      | 3%      | 97.81%              |
| Percent diagnosed (2015)                    | 66%    | 62%     | 71%     | 99.24%              |
| Progression (cirrhosis to HCC)              | 3.4%   | 2.5%    | 4.5%    | 99.56%              |
| Progression (HCC 1st year to LRD)           | 70.7%  | 56.3%   | 75.2%   | 99.70%              |
| Healthcare cost (HCC)                       | 16,944 CHF | 9,918 CHF | 26,480 CHF | 99.80%              |
| Standardized mortality ratio (injection drug use) | 5.5    | 4.6     | 6.4     | 99.85%              |
| Healthcare cost (decompensated cirrhosis)   | 20,347 CHF | 17,066 CHF | 22,908 CHF | 99.89%              |
| Healthcare cost (liver transplant)           | 125,102 CHF | 105,665 CHF | 144,500 CHF | 99.92%              |
| Progression (decompensated cirrhosis to LRD)| 3.6%   | 2.9%    | 4.4%    | 99.95%              |
| Subsequent year progression (HCC to LRD)    | 16.2%  | 12.8%   | 20.3%   | 99.97%              |
| Healthcare cost (subsequent year liver transplant) | 19,323 CHF | 16,321 CHF | 22,325 CHF | 99.99%              |
| Screening cost (anti-HCV test)               | 25 CHF | 23 CHF  | 27 CHF  | 100.00%             |
times higher than in either intervention scenario. The intervention’s higher upfront costs are therefore offset by reductions in future healthcare costs. In all three scenarios, a major change in screening costs occurs between 2021 and 2023, falling from more than 5 million CHF annually to less than 125,000 CHF annually. These costs are estimated by assuming that the current number of patients diagnosed annually is maintained, and uses formulas to estimate the number of screenings needed from the proportion of prevalent and diagnosed cases [15].

Expanding treatment access to all patients aged 15 years and over, regardless of fibrosis stage, over the next 15 years, was found to be cost-effective by 2018 at the 31,000 CHF price. While this is not sufficient to break even by 2031, it lends further credence to other analyses which have shown that early treatment of HCV is not only beneficial to disease burden, but also cost-effective [13, 22, 23]. Net-zero cost analysis found that a 27,900 CHF treatment price could achieve break-even in direct costs by 2031.

Finally, this analysis has some limitations which should be considered when evaluating the results. The high diagnosis coverage (66%) does not necessarily translate to patients linked to care, meaning that some work may still be required to identify patients for treatment. In addition, the analysis assumed no risk of reinfection after cure, an assumption which could lead to an overestimation of cost-effectiveness. Another limitation of this analysis is that the results do not consider extrahepatic manifestations of HCV, associated lost productivity, or other aspects of societal return on investment. Recent studies suggest that extrahepatic manifestations contribute substantially to the economic burden of HCV [24, 25]. Achieving SVR, especially at an early stage of disease, can attenuate the associated disease and economic burdens of these extrahepatic manifestations [26, 27]. Including this in the analysis would likely show even greater cost savings. Similarly, if we had included the loss in productivity and decreased societal engagement (due to stigma, strained relationships, etc.) associated with ongoing HCV infection (and subsequently improved by achieving SVR), the cost savings associated with treating HCV would be expected to improve. Lastly, the analysis does not incorporate any future changes in price associated with the introduction of generic drugs. Beginning in 2026, treatment prices are estimated to drop to 70% of the initial 2016 prices due to patent expiration. This would make the key outcomes of the economic impact analysis more favourable. However, it is possible that new therapies will be introduced before the patent expiration, which would counterbalance the effect of generic price reductions.

Conclusions
This analysis shows baseline HCV disease burden in Switzerland declining over the next 15 years, even with treatment restricted to ≥F2 patients. Expanding treatment to ≥F0 patients and increasing the number of treated patients (considering a price of 27,900–31,000 CHF per treatment) will result in a larger impact on disease burden and is cost-effective or cost-saving when considering a variety of measures. This confirms that further reductions in treatment prices improve cost-effectiveness and create conditions suitable for positive returns on the investment. To supplement this cost-effectiveness analysis, a comprehensive budget impact analysis would be essential to determine the financial consequences and affordability of implementing such strategies.

Acknowledgements
We are grateful to Dr. Jörg Indermitte from the Federal Office of Public Health and Ivane Gamkrelidze from the Center for Disease Analysis Foundation (CDAF) for their contributions to the development of this analysis. Additionally, we would like to thank Helen Nde and Sarah Robbins from CDAF for their help drafting and reviewing the manuscript. Finally, we appreciate the input of Prof. Beat Müllhaupt, Dr. Florian Bihl, Prof. Daniel Lavanchy and Dr. David Semela, who provided data and input for the disease burden analysis.

Funding source
This work was funded by the Swiss Federal Office of Public Health

Conflicts of interest
S. Blach and H. Razavi are employees of the Center for Disease Analysis Foundation (CDAF) and have not received any remuneration from pharmaceutical companies. H. Razavi has been a member of advisory boards for Gilead, AbbVie and Janssen pharmaceuticals; all proceeds went to the CDAF. He is the managing director of Center for Disease Analysis (CDA). The CDAF has received grants from CDC Foundation, John C Martin Foundation, The Association of State and Territorial Health Officials (ASTHO), Zeshan Foundation, Vaccine Impact Modelling Consortium, WHO WPRO, WHO Geneva, Swiss Federal Office of Public Health, Brazil MoH, Center for Disease Analysis and private donors. The CDA has received research funding from Gilead Sciences, AbbVie and Intercept Pharma. P. Bruggmann is a consultant/advisor and has received research/travel grants from AbbVie, Gilead Sciences and Merck/MSD. F. Negro has received research funding from Gilead Sciences and is a consultant/advisor for Gilead, AbbVie and MSD.

References
1. Zahnd C, Brezzi M, Bertisch B, Giudici F, Keiser O. Situation Analysis on hepatitis B and C in Switzerland [Online]. Federal Office of Public Health; 2017 [Available from: www.bag.admin.ch/situationanalyse-hepatitis].
2. Uchtenhagen A. Heroin-assisted treatment in Switzerland: a case study in policy change. Addiction. 2010;105(1):29–37. doi: http://dx.doi.org/10.1111/j.1360-0443.2009.02741.x. PubMed.
3. Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, et al. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS. 2015;10(6):. doi: http://dx.doi.org/10.1371/journal.pone.0125214. PubMed.
4. Swiss Hepatitis Strategy 2014–2030. To Act Now! Process Paper - A Living Document. http://www.hepatitis-schweiz.ch/files/Dokumente/Process_Paper_2nd_version_final.pdf. 2015.
5. World Bank. GDP per capita (current US$) Washington, D.C. 2015 [Available from: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD].
6. Leblibicioglu H, Arends JE, Ozaraz R, Corti G, Santos L, Boesecke C, et al., ESGH (part of ESCMID). Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. Antiviral Res. 2018;150:9–14. doi: http://dx.doi.org/10.1016/j.antiviral.2017.12.001. PubMed.
7. Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, et al.; Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol. Hepatol. 2017;2(3):161–76. doi: http://dx.doi.org/10.1016/S2468-1253(16)30181-9. PubMed.
8. WHO. Global Health Sector Strategy on Viral Hepatitis, 2016–2021 Towards Ending Viral Hepatitis. World Health Organization; 2016.
9. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–14. doi: http://dx.doi.org/10.7326/0003-4819-144-10-200605160-00004. PubMed.
10. Federal Office of Public Health. Swiss mandatory notifications for hepatitis C per canton, FOPH/CD/EPURIC. 29.08.16. 2016.
11. Health IMS. IMS Health MIDAS Data 2013 [updated 1/1/2013. Available from: http://www.imshealth.com/.

No commercial reuse without permission. See http://enmh.ch/en/services/permissions.html.
Quantum leaps, microeconomics, and the treatment of patients with advanced fibrosis. J Viral Hepat. 2017;24(9):750–8. doi: http://dx.doi.org/10.1111/jhev.12704. PubMed.

Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, et al.; PITER Collaborating Group. Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort. Hepatology. 2017;66(6):1814–25. doi: http://dx.doi.org/10.1002/hep.29399. PubMed.

Cacoub P, Buggisch P, Carrion JA, Cooke GS, Zignego AL, Beckerman R, et al. Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in Europe. J Viral Hepat. 2018;25(7):811–7. doi: http://dx.doi.org/10.1111/jhev.12881. PubMed.

Cacoub P, Vautier M, Desbois AC, Saadoun D, Younossi Z. Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. Aliment Pharmacol Ther. 2018;47(1):123–8. doi: http://dx.doi.org/10.1111/apt.14382. PubMed.

Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67(11):2025–34. doi: http://dx.doi.org/10.1136/gutjnl-2018-136234. PubMed.

Mehle P, Engels EA, Li R, Torres HA, Hwang LY, Brown EL, et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut. 2018;67(3):553–61. doi: http://dx.doi.org/10.1136/gutjnl-2017-313963. PubMed.

Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290(2):228–37. doi: http://dx.doi.org/10.1001/jama.290.2.228. PubMed.

Thein HH, Krah M, Kalder JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol. 2005;100(3):643–51. doi: http://dx.doi.org/10.1111/j.1572-0241.2005.00976.x. PubMed.

Li S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156(4):279–90. doi: http://dx.doi.org/10.7326/0003-4819-156-4-201202210-00005. PubMed.

Hugan LM, Yang Z, Ehteshami M, Schinaifi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat. 2013;20(12):847–57. doi: http://dx.doi.org/10.1111/jhev.12111. PubMed.